Global Dilated Cardiomyopathy Therapeutics Market to Reach $485.3 Million by 2030
The global market for Dilated Cardiomyopathy Therapeutics estimated at US$347 Million in the year 2022, is projected to reach a revised size of US$485.3 Million by 2030, growing at a CAGR of 4.3% over the analysis period 2022-2030. Angiotensin II Receptor Blockers (ARBs), one of the segments analyzed in the report, is projected to record 4.9% CAGR and reach US$234.2 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Beta-Blockers segment is readjusted to a revised 4.2% CAGR for the next 8-year period.The U.S. Market is Estimated at $102.4 Million, While China is Forecast to Grow at 4% CAGR
The Dilated Cardiomyopathy Therapeutics market in the U.S. is estimated at US$102.4 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$85.2 Million by the year 2030 trailing a CAGR of 4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.2% and 3.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.Select Competitors (Total 47 Featured) -
- Array BioPharma, Inc.
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Janssen Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Novartis International AG
- Pfizer, Inc.
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.
- Vericel Corporation
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and the publisher's Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Dilated Cardiomyopathy Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 2: World Historic Review for Dilated Cardiomyopathy Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 3: World 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
- Table 4: World Recent Past, Current & Future Analysis for Aldosterone Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 5: World Historic Review for Aldosterone Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 6: World 16-Year Perspective for Aldosterone Antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Angiotensin-Converting Enzyme (ACE) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 8: World Historic Review for Angiotensin-Converting Enzyme (ACE) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 9: World 16-Year Perspective for Angiotensin-Converting Enzyme (ACE) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 10: World Recent Past, Current & Future Analysis for Angiotensin II Receptor Blockers (ARBs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 11: World Historic Review for Angiotensin II Receptor Blockers (ARBs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 12: World 16-Year Perspective for Angiotensin II Receptor Blockers (ARBs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 13: World Recent Past, Current & Future Analysis for Beta-Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 14: World Historic Review for Beta-Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 15: World 16-Year Perspective for Beta-Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 16: World Dilated Cardiomyopathy Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
- UNITED STATES
- Dilated Cardiomyopathy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 17: USA Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 18: USA Historic Review for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 19: USA 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists for the Years 2014, 2023 & 2030
- CANADA
- Table 20: Canada Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 21: Canada Historic Review for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 22: Canada 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists for the Years 2014, 2023 & 2030
- JAPAN
- Dilated Cardiomyopathy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 23: Japan Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 24: Japan Historic Review for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 25: Japan 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists for the Years 2014, 2023 & 2030
- CHINA
- Dilated Cardiomyopathy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 26: China Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 27: China Historic Review for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 28: China 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists for the Years 2014, 2023 & 2030
- EUROPE
- Dilated Cardiomyopathy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 29: Europe Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 30: Europe Historic Review for Dilated Cardiomyopathy Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 31: Europe 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
- Table 32: Europe Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 33: Europe Historic Review for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 34: Europe 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists for the Years 2014, 2023 & 2030
- FRANCE
- Dilated Cardiomyopathy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 35: France Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 36: France Historic Review for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 37: France 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists for the Years 2014, 2023 & 2030
- GERMANY
- Dilated Cardiomyopathy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 38: Germany Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 39: Germany Historic Review for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 40: Germany 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists for the Years 2014, 2023 & 2030
- ITALY
- Table 41: Italy Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 42: Italy Historic Review for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 43: Italy 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists for the Years 2014, 2023 & 2030
- UNITED KINGDOM
- Dilated Cardiomyopathy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 44: UK Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 45: UK Historic Review for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 46: UK 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists for the Years 2014, 2023 & 2030
- REST OF EUROPE
- Table 47: Rest of Europe Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 48: Rest of Europe Historic Review for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 49: Rest of Europe 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists for the Years 2014, 2023 & 2030
- ASIA-PACIFIC
- Dilated Cardiomyopathy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 50: Asia-Pacific Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 51: Asia-Pacific Historic Review for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 52: Asia-Pacific 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists for the Years 2014, 2023 & 2030
- REST OF WORLD
- Table 53: Rest of World Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 54: Rest of World Historic Review for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 55: Rest of World 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists for the Years 2014, 2023 & 2030
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Array BioPharma, Inc.
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Janssen Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Novartis International AG
- Pfizer, Inc.
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.
- Vericel Corporation
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 197 |
Published | March 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 347 Million |
Forecasted Market Value ( USD | $ 485.3 Million |
Compound Annual Growth Rate | 4.3% |
Regions Covered | Global |